Cargill Makes Multimillion Investment in French Alginates Plant
Cargill invests to upgrade its alginate production plant in in Lannilis, Brittany, France.
Cargill is investing $15 million to upgrade and expand its alginates production plant in Lannilis, Brittany, France. The investment will fund several upgrades to the plant, including capacity expansion, safety upgraded, and improved wastewater processing. The production plant is located in close proximity to the French coast, where Cargill works with local fisherman to secure a source of fresh brown seaweed, from which the alginate is extracted.
Cargill offers a variety of alginates with gelling and thickening functionalities for applications in pharmaceuticals, food and beverages.
Source: Cargill
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
